Perflutren Lipid Microsphere Intravenous Suspension
Chronic Kidney Disease
Explore 30 assets in Chronic Kidney Disease →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03907657CT.gov Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Perflutren Lipid Microsphere Intravenous Suspension (this asset) | UNC Lineberger Comprehensive Cancer Center | P2 | CCC · 55 |
| Clopidogrel | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Sodium Ferric Gluconate | Watson Pharmaceuticals | P4 | BB |
| Semaglutide | Institute of Liver and Biliary Sciences, India | P4 | BB |
| Aspirin | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Watson Pharmaceuticals | P4 | BB |
| Retatrutide | Eli Lilly and Company | P3 | B |
| Citric Acid Monohydrate | Alfredo Di Leo | P4 | B |
| Ropivacaine | The First People's Hospital of Lianyungang | P4 | B |
+42 more in the Chronic Kidney Disease cohort
Other indications for Perflutren Lipid Microsphere Intravenous Suspension
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P2/3 | B · 60 |
| Breast Cancer | — | P2/3 | B · 59 |
| Von Hippel-Lindau Disease | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Perflutren Lipid Microsphere Intravenous Suspension in Chronic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/perflutren-lipid-microsphere-intravenous-suspension-chronic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →